Interleukin-10 and -12 Predict Chemotherapy-Associated Toxicity in Esophageal Adenocarcinoma  by Schauer, Matthias C. et al.
ORIGINAL ARTICLE
Interleukin-10 and -12 Predict Chemotherapy-Associated
Toxicity in Esophageal Adenocarcinoma
Matthias C. Schauer, MD,* Bernhard Holzmann, PhD,† Matthias Peiper, PhD,* Helmut Friess, PhD,†
Wolfram Trudo Knoefel, PhD,* and Joerg Theisen, PhD†
Introduction: Chemotherapy-associated mucositis often prevents
completion of an entire chemotherapy cycle. The underlying patho-
physiology of chemotherapy-associated mucositis has not been well
established. The individual immunologic predisposition of patients
seems to play an important role.
Methods: One hundred fifty-six patients with locally advanced or
metastatic esophageal adenocarcinoma received neoadjuvant che-
motherapy with cisplatin, 5-fluorouracil, and leucovorin followed by
resection. Before the neoadjuvant therapy, monocytes were isolated
from blood samples and were stimulated with lipopolysaccharide
and interferon. An enzyme-linked immunosorbent assay was used to
measure interleukin (IL)-10 and -12 levels and correlated with
patients’ clinical course.
Results: Twenty-two patients (14,1%) developed grade III to IV
mucositis (according to the NCI-Common toxicity criteria scales)
within the neoadjuvant chemotherapy. Pretherapeutic low IL-10
(24.1 pg/ml) and high IL-12 (5500 pg/ml) levels were signifi-
cantly associated with mucositis causing a therapy interruption or
even cessation. Patients with high IL-10 (43.6 pg/ml) and low
IL-12 (4408.5 pg/ml) levels had an uneventful neoadjuvant che-
motherapy.
Conclusions: Pretherapeutic individual monocyte function is corre-
lated with the development and the grade of chemotherapy induced
mucositis. This knowledge might help us in predicting the grade of
mucositis and in understanding the genesis regarding the association
to pro- and anti-inflammatory effects of monocyte cytokines.
Key Words: Cytokines, Neoadjuvant chemotherapy, Toxcicity,
Mucositis, Mucositis-associated sepsis.
(J Thorac Oncol. 2010;5: 1849–1854)
A multimodal therapy concept of locally advanced adeno-carcinomas of the distal esophagus (Barrett’s carcinoma),
consisting of a neoadjuvant chemotherapy with cisplatin,
5-fluorouracil (5FU), and leucovorin (PLF) and following
resection, results in a better prognosis with a 5-year survival
rate of up to 70% in responding patients.1 However, neoad-
juvant chemotherapy often induces toxic side effects. Aside
from the bone marrow, a major dose-limiting organ is the
intestine.2 The debilitating effects of mucositis can result in
unplanned treatment interruptions or even premature cessa-
tion of treatment.3,4 Alimentary tract mucositis is manifest by
a range of symptoms depending on the area that is most
affected. Symptoms include ulcerations, nausea and vomit-
ing, diarrhea, constipation, and abdominal pain.5,6 Mucositis
is associated with gut barrier disruption and is related to an
imbalance between proliferation and apoptosis of gut epithe-
lial cells.7,8
Oral mucositis, for example, is a common painful
dose-limiting toxicity of chemotherapy with 5FU that often
interferes with patients’ quality of life and nutrition.3,9–11 In
granulocytopenic patients, the ulcerations that accompany
mucositis are frequent portals of entry for indigenous bacteria
often leading to bacteremia or even sepsis. The condition
seems to represent a sequential interaction of the mucosal
cells, tissues, proinflammatory cytokines, and local environ-
mental factors such as lysosomal proteolytic activity, micro-
organisms, and saliva.10,12–14 Despite recent studies, the un-
derlying mechanisms of gastrointestinal damage induced by
cancer chemotherapy remain only partly understood. The
injury caused by cytotoxic chemotherapy in mucosa is me-
diated by a range of pathways including mitogen-activated
protein kinase, nuclear factor (NF)-B, and other cytokines.
Activation of these injurious signaling pathways leads to an
excessive influx of immune cells including macrophages into
the mucosa, thus initiating an inflammatory response.15,16
Proinflammatory cytokines have the capacity to initiate epi-
thelial signaling, thus causing further tissue damage. In this
context, interleukin (IL)-10 and -12 seem to play key roles as
antiinflammatory and proinflammatory cytokines.17–20
A better understanding of the pathophysiology and a
possible predisposition of patients at risk for the development
of a chemotherapy-induced mucositis is required. The pre-
therapeutic identification of these patients may help to target
appropriate treatment strategies very early and avoid a dose
limitation of the chemotherapy.
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A prospective study was performed to address the ques-
tion of whether impaired monocyte function and accordingly the
production of IL-10 and -12 before chemotherapy may be
related to the development and course of grade IV mucositis.
PATIENTS AND METHODS
Patient Population and Study Design
One hundred fifty-six patients with locally advanced or
metastatic adenocarcinoma of the distal esophagus (Barrett’s
carcinoma) undergoing a multimodal therapy were included in a
prospective study. The clinical profiles of all patients analyzed
are detailed in Table 1. Patients with acquired or inherited
immunodeficiency and patients receiving immunosuppressive
medication were excluded from the study. The study was ap-
proved by institutional review board, and written informed
consent was given by all participating patients.
All patients had tumors located in the distal third of the
esophagus within areas of specialized intestinal-type columnar
epithelium (Barrett’s esophagus). In the primary staging with
endoscopy, endosonography, and computed tomography scan,
all 156 patients showed a locally advanced cancer with infiltra-
tion of all esophageal layers (T3 category). Eighty-one percent of
these patients showed enlarged locoregional lymph nodes (Table
1). All patients received neoadjuvant chemotherapy. For poly-
chemotherapy, patients received one to two cycles of PLF
(cisplatin, leucovorin, and 5FU) during a period of 6 weeks per
cycle (5FU, 2000 mg/bovine serum albumin continuously over
24 hours for 6 weeks; leucovorin, 500 mg for 2 hours every 7
days; and cisplatin, 50 mg/bovine serum albumin for 1 hour
every 14 days). After 4 to 6 weeks of recovery of the patients,
the clinical response was evaluated by the comparison of the
pretherapeutic and posttherapeutic endoscopy, endosonography,
and computed tomography scan. All patients finally underwent
an esophageal resection with reconstruction with a gastric tube
(modified Ivor-Lewis). The histopathologic response was as-
sessed according to Becker in the postoperative specimen.21 Tu-
mors with less than 50% viable tumor cells of the primary Barrett’s
carcinoma accounted to responding cancers, whereas more than
50% viable tumor cells signified a nonresponse cancer.
From each patient, a venous blood sample was collected at
least 1 day before the first cycle of chemotherapy. For the
inclusion of patients in the group of severe mucositis, established
criteria were used.22 Patients were categorized according to the
National Cancer Institute-Common Toxicity Criteria scales (gas-
trointestinal category for specific sites). Patients were included
in the mucositis group only if corresponding grade III or IV
toxicity caused prolonged chemotherapy intervals, reduced che-
motherapeutic concentration, or a cessation of chemotherapy
treatment.
Monocyte Cytokine Secretion
Peripheral blood mononuclear cells were isolated from 25
ml of heparinized blood using Ficoll-metrizoate density gradient
centrifugation, and monocytes were purified by plastic adher-
ence. Duplicate cultures of 5  104 monocytes/well were incu-
bated with 1 g/ml interferon (IFN)- (Biosource International,
Nivelles, Belgium) for 16 hours in 1 ml of Roswell Park
Memorial Institute 1640 medium supplemented with 10% fetal
calf serum. Thereafter, 1 g of endotoxin from Eschericha coli
serotype 0127:B8 (Sigma Chemical Co., St. Louis, MO) was
added at a final concentration of 1 g/ml, and cells were
incubated for an additional 24 hours at 37°C and 6% carbond-
ioxide. Supernatants were centrifuged at 3360 g for 10 minutes
to remove residual cells and stored at 20°C. The levels of
IL-12 (Amersham Biosciences, Braunschweig, Germany) and
IL-10 (Biosource) in supernatants of stimulated monocytes were
determined by the enzyme-linked immunosorbent assay accord-
ing to the manufacturer’s instructions. All cytokine assays were
standardized by including a titration of purified recombinant
cytokine of known concentration. The sensitivity of the assays
was 3 pg/ml (IL-12) and 1 pg/ml (IL-10). The absorbance of the
samples was determined on a MRX microplate reader (Dyna-
tech, Denkendorf, Germany) using 450 nm as the primary and
630 nm as the reference wave length.
Statistical Analysis
Comparison between groups was performed with the
Student t test or 2 test. Overall survival rates were calculated
by the Kaplan–Meier method and included operative mortal-
ity. Differences in survival between groups were shown with
the log-rank test. The significance level was set at p  0.05.
Analyses were performed using the SPSS version 14.5 sta-
tistical package (SPSS, Chicago, IL).
TABLE 1. Clinical Data of Patients
Characteristics
No. of
Patients
(n  156)
Mucositis
Grade III–IV
Incidence
(n  22) p
Age (yr)
Mean  SEM 55.7  10.7 56.6  11.6 0.69
Range 51 (25–76) 43 (27–70)
Sex
Male 120 14 0.169
Female 36 8
Chemotherapy
1 cycle 34 15
2 cycles 122 7 0.001
TNM category
T0 11 0 0.22
T1 8 1
T2 65 9
T3 60 8
T4 12 4
N0 65 7 0.36
N1 91 15
M0 120 16 0.65
M1 36 6
R-category
R0 118 14 0.39
R1 24 5
R2 14 3
R0, complete resection; R1, cancer reaching microscopically up to the margin of
resection; R2, cancer reaching macroscopically up to the margin of resection; TNM,
tumor, node, metastasis.
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RESULTS
Patient’s Demographical Data and Variables
Associated with Mucositis
Demographic information of the study population is
summarized in Table 1. Mean age of our patients was
55.7  10.7 years. One hundred twenty patients were men
and 36 were women. One hundred twenty-two patients
completed the multimodal therapy with three courses of
chemotherapy and following resection. Thirty-four pa-
tients did not complete the neoadjuvant chemotherapy but
were subsequently resected.
Twenty-two (14.1%) of 156 patients developed grade
III to IV mucositis (according to the National Cancer Insti-
tute-Common Toxicity Criteria scales) within neoadjuvant
chemotherapy for Barrett’s carcinoma with PLF (Table 1).
The accompanying side effects with diarrhea, water-electro-
lyte imbalance, malnutrition, oral and abdominal pain, fever,
and mucosal barrier disruption resulted in unplanned therapy
interruptions7 or even cessations.15 In cases of treatment
cessations, patients were operated after their recovery without
the second or third chemotherapy cycle.
Development and grade of mucositis were not related to
age, sex, or any tumor characteristics such as tumor size,
depth of invasion, lymph node involvement, metastases, or
grading of neither the pretherapeutic staging nor the postop-
erative pathologic staging of the resected specimen (Table 1).
All 15 patients who had to quit chemotherapy because of
severe mucositis received only 6 weeks of chemotherapy,
whereas the full neoadjuvant regimen (122 patients) consisted
of 12 weeks of chemotherapy.
In comparison of responding versus nonresponding
patients (65 versus 91 patients), one can find a highly signif-
icant correlation with the resection status (R) (p 0.001) and
the lymph node status (N) (p  0.001). In correspondence,
responding patients and patients without lymph node metas-
tases (65 patients) show a significant survival benefit (Figure
1; p  0.001).
Pretherapeutic IL-10 and -12 Synthesizing
Capability
Low levels of pretherapeutic IL-10 under lipopolysac-
charide and IFN stimulation were associated with high-grade
mucositis and following unplanned interruptions of chemo-
therapy (p  0.012; Figure 2). Mean IL-10 value in patients
with high-grade mucositis was 24.1 pg/ml, whereas patients
without mucositis showed a mean level of 43.6 pg/ml. Pa-
tients with initially high levels of IL-10 did not develop
mucositis-associated complications. Ninety-two percent of
patients with levels higher than 50 pg/ml did not have any
problems with mucositis.
The pretherapeutic IL-12–synthesizing capability was
also significantly associated with the development of mucosi-
tis (p  0.04; Figure 3). Pretherapeutic high IL-12 levels are
linked to grade III to IV mucositis. In patients with severe
mucositis, the mean IL-12 value was initially 7877.4 pg/ml,
whereas patients with an untroubled chemotherapy showed a
mean IL-12 level of 4408.5 pg/ml. Ninety-eight percent of
patients with an IL-12 level less than 5500 pg/ml do not
complain of any mucositis-associated symptoms during their
chemotherapy, whereas patients with IL-12 levels greater
than 5500 pg/ml more frequently interrupt the chemotherapy
as a consequence of mucositis (p  0.045).
Levels of IL-10 and -12 were not influenced by age,
sex, or tumor stadium. Neither depth of invasion nor lymph
node status or grading had an influence on IL values. The
pretherapeutic IL levels did not have a significant impact on
response, other chemotherapy-induced side effects such as
neutropenia, bone marrow suppression, or renal function.
There was no association to the postoperative course, com-
plications, or long-term survival.
DISCUSSION
A multimodal therapy concept with neoadjuvant che-
motherapy and following resection in patients with Barrett’s
FIGURE 2. Pretherapeutic monocyte interleukin (IL)-10 pro-
duction on consecutive exposure to lipopolysaccharide and
interferon has significant impact on grade of chemotherapy-
induced mucositis. p  0.036.
FIGURE 1. Impact of tumor response after neoadjuvant
chemotherapy on survival. p  0.001. IL, interleukin.
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carcinoma results in a survival benefit in patients who re-
spond to the neoadjuvant therapy.1 In our study, we could
reconfirm the histopathologic response as a strong predictor
of long-term survival. Equally, we could reconfirm the resec-
tion status and the lymph node status as strong predictors
even after chemotherapy.1 However, corresponding to the
literature, more than 14% of our patients had to interrupt or
even stop their neoadjuvant chemotherapy because of severe
mucositis with consequent pain, nausea, electrolyte imbal-
ance, and malnutrition.1 Many studies either try to differen-
tiate responder from nonresponder early during chemother-
apy with positron emission tomography23 or try to predict
response with the genetic finger print of the tumor before
starting the therapy to prevent the treatment of nonresponding
patients.24 Until now, it is not possible to identify nonre-
sponding patients, and therefore, these patients are kept from
the time lag of the resection and the adverse effects of the
chemotherapy with regard to the operation.
Similarly, prediction of serious side effects of chemo-
therapy on the function of the bone marrow, renal function
and mucosa, and their impact on the further therapy regimen
was not feasible. Gastrointestinal mucositis after cancer che-
motherapy is an increasing problem that is essentially un-
treatable once established, although it gradually remits. Opi-
oid analgesia provides inadequate relief.9 Various strategies
including antibiotic treatment, parenteral analgesia, paren-
teral nutrition, and electrolyte balance are used to counteract
the most adverse effects of mucositis in patients.2 Despite this
supporting treatment, 14% of our patients had mucositis
grade III to IV. Many different symptomatic treatments of
mucositis with, for example, polyvinylpyrrolidone-sodium
hyaluronate, iberogast, bisbenzylisoquinoline alkaloidal com-
pound, spondin 1  keratinocyte growth factor, epidermal
growth factor, or IL-11 have been used with only moderate
success.25–32 The treatment remains difficult, because the
pathobiology of alimentary tract mucositis is complex, and
there is limited information about the events that lead to the
mucosal damage.
Pathohistologically, chemotherapy induces apoptotic
cell death and loss of proliferation in the intestinal crypt
epithelium.2,33–35 This results in crypt-loss, villus atrophy,
and eventually in ulcerations with barrier impairments and
malabsorption.36 In addition to the microflora, the goblet
cells, and the mucin, one of the principal defense factors of
the gastrointestinal mucosa, various transcription factors, and
proinflammatory cytokines are thought to play important
roles in pathogenesis of mucositis.10,14,35 The exact nature,
duration, and severity of the mucosal dysfunction that devel-
ops seem to depend on both treatment and host factors.16,37
The current hypothesis for the diversified development of
mucositis was first introduced in 2004.22 Initially, cytotoxic
chemotherapy encompasses the primary damage of the mu-
cosa, which results in the upregulation of transcription factors
including NF-B and subsequent activation of cytokine and
stress response genes.11,13,38 A cascade of cytokines starting
with IL-1, IL-6, IL-12, and tumor necrosis factor (TNF)
causes direct tissue damage and provide positive feedback to
amplify the process.2,13,39 The result of these proinflamma-
tory cytokines is widespread apoptosis that occurs within
various epithelial and connective tissue compartments that
make up the mucosal tissue. Furthermore, bacteria in dam-
aged mucosa may directly stimulate NF-B and proinflam-
matory cytokine expression, thereby potentiating tissue dam-
age.22,40 In our opinion, this critical phase determines
interindividually the grade of mucositis depending on the
monocyte function. In this context, IL-10 and -12 seem to
play a key role. IL-12 is involved in the differentiation of
naive T cells into T helper (TH) 0 cells and their further
development into TH1 or 2 cells. It is known as a T-cell–
stimulating factor for their growth and function. It stimulates
the production of IFN- and TNF- from natural killer cells.
IL-12 mediates the enhancement of the cytotoxic activity of
natural killer cells and CD8-positive cytotoxic T lympho-
cytes.41,42 These effects on the cellular immune reaction and
its antiangiogenic activity partly account for the etiology of
alimentary tract mucositis.17,18
The prevention or diminution of these responses by
antiinflammatory cytokines such as IL-10, IL-11, IL-15,
TGF-, and TGF- is beneficial.43–45 It could be shown that
these cytokines together with keratinocyte growth factor can
result in a 3-fold to 4-fold increase in the number of intestinal
stem cells that survive a dose of radiochemotherapy and,
therefore, an increased animal survival in the mouse mo-
del.24–26 Treatment with free radical scavengers, such as
amifostine, reduces the severity of mucositis and increases
the therapeutic dose tolerated by patients.30
IL-10 has pleiotropic effects in immunoregulation and
inflammation. It down-regulates the expression of TH1 cyto-
kines, major histocompatibility complex class II antigens, and
costimulatory molecules on macrophages.19,20 This cytokine
can block NF-B activity and inhibit the synthesis of IFN-,
IL-2, IL-3, TNF-, and granulocyte-macrophage colony-
stimulating factor. Therefore, this cytokine is an essential
immunoregulator in the intestinal tract. A defect of IL-10
FIGURE 3. Pretherapeutic monocyte interleukin-12 produc-
tion on consecutive exposure to lipopolysaccharide and in-
terferon has significant impact on grade of chemotherapy-
induced mucositis. p  0.041.
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goes along with a disposition for chronic ulcerative mucositis
such as inflammatory bowel disease.46
In our study, the pretherapeutic monocyte function
could be significantly correlated with the grade of chemo-
therapy-induced mucositis for the first time. The great differ-
ences of grade of mucositis between patients receiving the
same chemotherapy may be at least partly be explained by
these results. Consistent with the proinflammatory role of
IL-12 with its central role in the cellular bound immune
defense as already mentioned, the IL-12 level of the prethera-
peutic stimulated monocytes are significantly higher (5500
pg/ml) in patients with high-grade mucositis causing ulcer-
ations with corresponding complications such as water-elec-
trolyte imbalance, abdominal pain, malnutrition, sometimes
even bacteremia, and accordingly cessation of the neoadju-
vant therapy.
However, IL-10, the most important representative for
antiinflammatory cytokines in the intestine, showed prethera-
peutic low levels under IFN stimulation in patients with
severe mucositis. This defect is already known to be signif-
icantly correlated with intestinal ulcerations in patients with
inflammatory bowl disease as already mentioned.46 Interest-
ingly, the pretherapeutic IL-10 and -12 levels both show a
significant difference in patients with versus without mucosi-
tis during their courses of chemotherapy. Thus, the patient’s
individual monocyte function seems to influence the devel-
opment of different grades of mucositis. Having the current
hypothesis of Sonis in mind, these results indicate that the
grade of intestinal ulcerations is determined in the third phase:
“signaling and amplification.” In patients with high risk for
mucositis (IL-12 5500 pg/ml and IL-10 24.1 pg/ml in the
pretherapeutic risk assessment), monocyte function is stimulated
from chemotherapy-induced mucosal damage and causes ulcer-
ations as a result of an excessive immune reaction. In patients
with low risk for severe mucositis (IL-12 5500 pg/ml and
IL-10 50 pg/ml), the inflammatory response is regulated by
IL-10, and chemotherapy-induced mucosal damage is re-
stored by intestinal stem cells.
In conclusion, our results confirm our assumption that
the individual grade of mucositis is closely associated with
the pretherapeutic monocyte function and their production of
proinflammatory and antiinflammatory cytokines. The pre-
diction of therapy-limiting mucositis can be possible in the
near future by analyzing the monocyte function with produc-
tion of IL-10 and -12. Besides, this knowledge needs further
evaluation for a possible treatment of chemotherapy-induced
complications.
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